Status:

COMPLETED

Comparative Evaluation of Various Combinable Magnetic Resonance (CMR) Pulse-sequences for Macrophage Imaging Using Ferucarbotran

Lead Sponsor:

Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)

Conditions:

Acute Myocardial Infarction

Eligibility:

All Genders

18-80 years

Phase:

PHASE2

PHASE3

Brief Summary

The aim of this study is to: * clarify whether macrophage imaging using ferucarbotran is able to delineate the region of myocardial infarction as accurate as gadolinium-based necrosis/fibrosis imagin...

Eligibility Criteria

Inclusion

  • acute myocardial infarction (STEMI or NSTEMI)

Exclusion

  • contraindication to CMR or Magnevist® or Resovist®

Key Trial Info

Start Date :

March 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT00886444

Start Date

March 1 2009

Last Update

November 7 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Robert-Bosch-Krankenhaus, Division of Cardiology

Stuttgart, Germany, 70376